John A. Tzaferis
Eli Lilly (United States)(US)
Publications by Year
Research Areas
Alzheimer's disease research and treatments, Computational Drug Discovery Methods, Cholinesterase and Neurodegenerative Diseases, Neuropeptides and Animal Physiology, Receptor Mechanisms and Signaling
Most-Cited Works
- → TREM2-mediated early microglial response limits diffusion and toxicity of amyloid plaques(2016)865 cited
- → A Plaque-Specific Antibody Clears Existing β-amyloid Plaques in Alzheimer's Disease Mice(2012)443 cited
- → Kappa opioid receptor stimulation decreases amphetamine-induced behavior and neuropeptide mRNA expression in the striatum(2001)42 cited
- → Expression of metabotropic glutamate receptors in rat meningeal and brain microvasculature and choroid plexus(2003)41 cited
- → O1‐10‐03: COMBINATION THERAPY WITH A PLAQUE‐SPECIFIC ABETA ANTIBODY AND BACE INHIBITOR RESULTS IN DRAMATIC PLAQUE LOWERING IN AGED PDAPP TRANSGENIC MICE(2014)7 cited
- → P4‐401: Combination Therapy with a Plaque‐Specific Abeta Antibody And A Bace Inhibitor Results in Dramatic Plaque Reduction in a Dose‐Dependent Manner in Aged Pdapp Transgenic Mice(2016)2 cited
- → P3–231: Biochemical and histological studies of leucine rich repeat kinase 2 (LRRK2)(2006)
- → O4‐04‐02: Investigation of dose‐responses and longitudinal effects of combination therapy with a plaque‐specific amyloid beta antibody and bace inhibitor in aged transgenic mice(2015)
- → P4–297: Standardization of beta‐amyloid reference peptides(2013)
- → Engagement of Amyloid‐Targeting Antibodies on Native Human and Murine Cerebral Amyloid Angiopathy CAA Containing Vessels(2025)